| Literature DB >> 31416668 |
Dylan Kwart1, Andrew Gregg1, Claudia Scheckel2, Elisabeth A Murphy3, Dominik Paquet4, Michael Duffield1, John Fak3, Olav Olsen1, Robert B Darnell3, Marc Tessier-Lavigne5.
Abstract
Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. Here we leveraged recent advances in induced pluripotent stem cell (iPSC) and CRISPR/Cas9 genome editing technologies to generate a panel of isogenic knockin human iPSC lines carrying APP and/or PSEN1 mutations. Global transcriptomic and translatomic profiling revealed that fAD mutations have overlapping effects on the expression of AD-related and endocytosis-associated genes. Mutant neurons also increased Rab5+ early endosome size. APP and PSEN1 mutations had discordant effects on Aβ production but similar effects on APP β C-terminal fragments (β-CTFs), which accumulate in all mutant neurons. Importantly, endosomal dysfunction correlated with accumulation of β-CTFs, not Aβ, and could be rescued by pharmacological modulation of β-secretase (BACE). These data display the utility of our mutant iPSCs in studying AD-related phenotypes in a non-overexpression human-based system and support mounting evidence that β-CTF may be critical in AD pathogenesis.Entities:
Keywords: Alzheimer’s disease; Aβ; CRISPR/Cas9; Rab5; amyloid precursor protein; amyloid-beta; beta-C-terminal fragment; endocytosis; induced pluripotent stem cell; presenilin; β-CTF
Mesh:
Substances:
Year: 2019 PMID: 31416668 DOI: 10.1016/j.neuron.2019.07.010
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173